Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$149.72 USD

149.72
115,022

-0.24 (-0.16%)

Updated Aug 16, 2024 11:37 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Cardinal Health's (CAH) Arm Receives FDA Nod for LYMPHOSEEK

by Zacks Equity Research

Cardinal Health's (CAH) Nuclear & Precision Health Solutions receive FDA approval for LYMPHOSEEK injection.

BD's (BDX) Milestone Pandemic Orders to Support Vaccinations

by Zacks Equity Research

BD (BDX) receives 2 billion pandemic orders for needles and syringes to support global COVID-19 vaccination efforts.

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.

AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System

by Zacks Equity Research

AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.

DENTSPLY SIRONA (XRAY) Boosts Clear Aligner Foothold With Buyout

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) to fortifies its presence further in the clear aligner market with the acquisition of Propel Orthodontics.

BD (BDX) Solidifies Foothold in Healthcare Cybersecurity

by Zacks Equity Research

BD's (BDX) authorization as a CNA is expected to allow it to provide customers with timely information about vulnerabilities in BD products available globally.

    Here's Why You Should Retain McKesson (MCK) Stock Right Now

    by Zacks Equity Research

    McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.

    Baxter (BAX) Unveils New Digital Health Module for PD Patients

    by Zacks Equity Research

    Baxter (BAX) introduces new clinical management resource within the Sharesource remote patient management platform for home dialysis patients.

    DVA vs. AMED: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    DVA vs. AMED: Which Stock Is the Better Value Option?

    LHC Group (LHCG) Expands Hospice Presence with New Buyout

    by Zacks Equity Research

    LHC Group (LHCG) agrees to purchase Heart of Hospice to extend its hospice footprint in five states.

      Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio

      by Zacks Equity Research

      Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.

        Here's Why You Should Retain Allscripts (MDRX) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

        Here's Why You Should Retain PRA Health (PRAH) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

        Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

        by Zacks Equity Research

        Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.

        Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark

        by Zacks Equity Research

        Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.

        Here's Why You Should Retain PerkinElmer (PKI) Stock Now

        by Zacks Equity Research

        PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.

        BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch

        by Zacks Equity Research

        BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.

        NextGen (NXGN) Announces Positive Telehealth Survey Results

        by Zacks Equity Research

        NextGen's (NXGN) recent survey indicates growing preference for telehealth services.

        Here's Why You Should Retain Patterson Companies (PDCO) Stock

        by Zacks Equity Research

        Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.

        Allscripts (MDRX), Lash Group Team Up for Better Patient Care

        by Zacks Equity Research

        Allscripts' (MDRX) Veradigm enters collaboration to streamline specialty medication management for medical clinics and practices across the nation.

        Here's Why You Should Retain Glaukos (GKOS) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

        Here's Why You Should Retain Accuray (ARAY) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.

        Here's Why You Should Retain Cardinal Health (CAH) Stock Now

        by Zacks Equity Research

        Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.

        Trina Mukherjee headshot

        3 Stocks to Bank on Rebounding Outpatient Home Health Industry

        by Trina Mukherjee

        Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well-poised to gain from the prospects.

        Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.